XENON AND COOLING THERAPY IN BABIES AT HIGH RISK OF BRAIN INJURY FOLLOWING POOR CONDITION AT BIRTH: A RANDOMISED OUTCOME STUDY (COOLXENON3 STUDY)
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Xenon (Primary)
- Indications Anaesthesia
- Focus Adverse reactions
- Acronyms CoolXenon3
- 15 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018.
- 15 Feb 2017 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2018.
- 28 Jan 2016 Accrual to date is 36% according to the United Kingdom Clinical Research Network record.